Can-Fite BioPharma Ltd. (TLV:CANF)
1.000
0.00 (0.00%)
At close: Dec 4, 2025
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
377.36K ILS
Profits / Employee
-5.93M ILS
Market Cap
51.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 35,686 |
| Danel (Adir Yeoshua) | 4,290 |
| Kamada | 420 |
| BrainsWay | 120 |
| Bait Bakfar | 227 |
| SofWave Medical | 126 |
| Ilex Medical | 178 |
| Novolog (Pharm-Up 1966) | 936 |
Can-Fite BioPharma News
- 12 days ago - Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025 - GuruFocus
- 16 days ago - Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment - GuruFocus
- 16 days ago - Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - GlobeNewsWire
- 18 days ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News - GuruFocus
- 18 days ago - Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival - GuruFocus
- 4 weeks ago - CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News - GuruFocus
- 2 months ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News - GuruFocus
- 2 months ago - Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment - GuruFocus